Results 51 to 60 of about 59,693 (345)

Pharmacologic inhibition by spironolactone attenuates experimental abdominal aortic aneurysms

Frontiers in Cardiovascular Medicine, 2023
BackgroundAbdominal aortic aneurysms (AAA) are characterized by vascular inflammation and remodeling that can lead to aortic rupture resulting in significant mortality. Pannexin-1 channels on endothelial cells (ECs) can modulate ATP secretion to regulate
Zachary Ladd, Gang Su, Joseph Hartman, Guanyi Lu, Sara Hensley, Gilbert R. Upchurch, Ashish K. Sharma   +6 more
doaj   +1 more source

Efficacy and Safety of Spironolactone in the Treatment of Resistant Hypertension：a Meta-analysis [PDF]

Zhongguo quanke yixue, 2022
BackgroundAs a special type of hypertension, resistant hypertension has complex etiology, is difficult to treat, and more likely to lead to target organ damage.
ZHANG Ping, ZOU Jing, GAO Cunzhou, WU Aiping, LI Rongshan
doaj   +1 more source

Spironolactone and colitis: Increased mortality in rodents and in humans [PDF]

, 2012
Background: Crohn's disease causes intestinal inflammation leading to intestinal fibrosis. Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality. We examined whether spironolactone is antifibrotic in the context
Akbar K. Waljee, Andres, Brenda W. Gillespie, Carter, Charlson, Chun, Deyo, Ersoy, Fan, Gullulu, Higgins, Huang, Ibrahim, Jarvis, Joel C. Joyce, Kamath, Kim, Kuehne, Kyne, Laura A. Johnson, Livak, Louis, Lyerly, Lyras, Mezzano, Nishimura, Ochs, Overdiek, Patel, Peter D.R. Higgins, Pitt, Powell, Rajagopalan, Sands, Semler, Shail M. Govani, Sungaila, Thannickal, Tian, Tox, Witteck   +40 more
core   +1 more source

Clinical Determinants and Prognostic Implications of Renin and Aldosterone in Patients with Symptomatic Heart Failure [PDF]

, 2020
Aims Activation of the renin-angiotensin-aldosterone system plays an important role in the pathophysiology of heart failure (HF) and has been associated with poor prognosis.
Anker, Stefan D., Dickstein, Kenneth, Duarte, Kevin, Ferreira, Joao Pedro, Girerd, Nicolas, Kobayashi, Masatake, Lamiral, Zohra, Lang, Chim C., Metra, Macro, Ng, Leong L., Preud'homme, Gregoire, Rossignol, Patrick, Samani, Nilesh J., Stienen, Susan, ter Maaten, Jozine M., van Veldhuisen, Dirk J., Voors, Adriaan A., Zannad, Faiez   +17 more
core   +4 more sources

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial

European Journal of Heart Failure, 2020
Asymptomatic patients with coronary artery disease (CAD), hypertension and/or type 2 diabetes mellitus (T2DM) are at greater risk of developing heart failure (HF). Fibrosis, leading to myocardial and vascular dysfunction, might be an important pathway of
P. Pellicori, J. Ferreira, B. Mariottoni, H. Brunner-la Rocca, F. Ahmed, J. Verdonschot, T. Collier, J. Cuthbert, J. Petutschnigg, B. Mujaj, N. Girerd, Arantxa González, A. Clark, F. Cosmi, J. Staessen, S. Heymans, R. Latini, P. Rossignol, F. Zannad, J. Cleland   +19 more
semanticscholar   +1 more source

National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland [PDF]

, 2004
Objective: To examine the epidemiology, primary care burden, and treatment of heart failure in Scotland, UK. Design: Cross sectional data from primary care practices participating in the Scottish continuous morbidity recording scheme between 1 April ...
Capewell, S., Chalmers, J., Kirkpatrick, M., MacIntyre, K., McAlister, F.A., McMurray, J., Murphy, N.F., Redpath, A., Simpson, C.R., Stewart, S.   +9 more
core   +2 more sources

Amiloride reduces portal hypertension in rat liver cirrhosis [PDF]

, 2010
Objective This study aimed to investigate the effect of amiloride on portal hypertension. Amiloride is known to inhibit Na(+)/H(+) exchangers on activated hepatic stellate cells.
Beitinger, Frigga, Bystron, Markus, De Toni, Enrico N., Gerbes, Alexander L., Hartmann, Anna C., Hennenberg, Martin, Steib, Christian J.   +6 more
core   +1 more source

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial [PDF]

, 2016
Introduction: Diabetes mellitus affects 9% of the European population and accounts for 15% of healthcare expenditure, in particular, due to excess costs related to complications.
Beige, Joachim, Currie, Gemma, Delles, Christian, Lindhardt, Morten, Mischak, Harald, Navis, Gerjan, Noutsou, Marina, Ortiz, Alberto, Persson, Frederik, Pontillo, Claudia, Rossing, Peter, Ruggenenti, Piero Luigi, Rychlik, Ivan, Spasovski, Goce, von der Leyen, Heiko   +14 more
core   +4 more sources

Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. [PDF]

PLoS ONE, 2012
OBJECTIVE: Aldosterone, one of the main peptides in renin angiotensin aldosterone system (RAAS), has been suggested to mediate liver fibrosis and portal hypertension.
Wei Luo, Ying Meng, Hong-Li Ji, Chun-Qiu Pan, Shan Huang, Chang-Hui Yu, Li-Ming Xiao, Kai Cui, Shu-Yuan Ni, Zhen-Shu Zhang, Xu Li   +10 more
doaj   +1 more source